JP2024514107A5 - - Google Patents
Info
- Publication number
- JP2024514107A5 JP2024514107A5 JP2023561019A JP2023561019A JP2024514107A5 JP 2024514107 A5 JP2024514107 A5 JP 2024514107A5 JP 2023561019 A JP2023561019 A JP 2023561019A JP 2023561019 A JP2023561019 A JP 2023561019A JP 2024514107 A5 JP2024514107 A5 JP 2024514107A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- car
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171520P | 2021-04-06 | 2021-04-06 | |
| US63/171,520 | 2021-04-06 | ||
| US202263311913P | 2022-02-18 | 2022-02-18 | |
| US63/311,913 | 2022-02-18 | ||
| PCT/US2022/023723 WO2022216864A1 (en) | 2021-04-06 | 2022-04-06 | Anti-cd19 antibodies and car-t structures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514107A JP2024514107A (ja) | 2024-03-28 |
| JP2024514107A5 true JP2024514107A5 (https=) | 2025-04-15 |
Family
ID=81387106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561019A Pending JP2024514107A (ja) | 2021-04-06 | 2022-04-06 | 抗ｃｄ１９抗体及びｃａｒ－ｔ構造体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240042032A1 (https=) |
| EP (1) | EP4320158A1 (https=) |
| JP (1) | JP2024514107A (https=) |
| KR (1) | KR20230166090A (https=) |
| AU (1) | AU2022255709A1 (https=) |
| BR (1) | BR112023020450A2 (https=) |
| CA (1) | CA3214283A1 (https=) |
| CL (3) | CL2023002968A1 (https=) |
| CO (1) | CO2023013500A2 (https=) |
| CR (1) | CR20230474A (https=) |
| IL (1) | IL306043A (https=) |
| MX (1) | MX2023011725A (https=) |
| PE (1) | PE20232050A1 (https=) |
| WO (1) | WO2022216864A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| WO2025087382A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海先博生物科技有限公司 | 靶向cd19的嵌合抗原受体的治疗用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| EP1296714B1 (en) * | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| BR112020024074A2 (pt) * | 2018-07-20 | 2021-02-17 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd19 |
| CN112521513B (zh) * | 2020-12-15 | 2021-08-24 | 青岛西凯生物技术有限公司 | 一种靶向cd19的嵌合抗原受体(car)及其应用 |
-
2022
- 2022-04-06 KR KR1020237034148A patent/KR20230166090A/ko active Pending
- 2022-04-06 IL IL306043A patent/IL306043A/en unknown
- 2022-04-06 BR BR112023020450A patent/BR112023020450A2/pt unknown
- 2022-04-06 CA CA3214283A patent/CA3214283A1/en active Pending
- 2022-04-06 WO PCT/US2022/023723 patent/WO2022216864A1/en not_active Ceased
- 2022-04-06 PE PE2023002807A patent/PE20232050A1/es unknown
- 2022-04-06 MX MX2023011725A patent/MX2023011725A/es unknown
- 2022-04-06 EP EP22719168.1A patent/EP4320158A1/en active Pending
- 2022-04-06 JP JP2023561019A patent/JP2024514107A/ja active Pending
- 2022-04-06 AU AU2022255709A patent/AU2022255709A1/en active Pending
- 2022-04-06 CR CR20230474A patent/CR20230474A/es unknown
-
2023
- 2023-09-22 US US18/473,057 patent/US20240042032A1/en active Pending
- 2023-10-04 CL CL2023002968A patent/CL2023002968A1/es unknown
- 2023-10-12 CO CONC2023/0013500A patent/CO2023013500A2/es unknown
-
2025
- 2025-06-16 US US19/239,816 patent/US20260048122A1/en active Pending
- 2025-09-24 CL CL2025002873A patent/CL2025002873A1/es unknown
- 2025-09-24 CL CL2025002872A patent/CL2025002872A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514107A5 (https=) | ||
| JP7539434B2 (ja) | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 | |
| JP7505885B2 (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| TWI761831B (zh) | 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途 | |
| TWI814525B (zh) | Ｃｄ７０結合分子及使用彼之方法 | |
| US12534532B2 (en) | CLL1-targeting antibody and application thereof | |
| JP2021530236A5 (https=) | ||
| KR20200015713A (ko) | 항-trbc1 항원 결합 도메인 | |
| JP2019506867A (ja) | Ｃｌｅｃ９ａ結合物質 | |
| JP7796034B2 (ja) | ヒトｃｄ４５ｒｃに特異的なキメラ抗原受容体およびその使用 | |
| JP2018522907A (ja) | Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞 | |
| JP2016516049A (ja) | 多量体化技術 | |
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2024507540A5 (https=) | ||
| CA3111804A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| JP2015501295A (ja) | 疾患を治療するのに有用な抗ヒトｓｅｍａ４Ａ抗体 | |
| US20240156962A1 (en) | Bcma-targeted car-t cell therapy of multiple myeloma | |
| TW202444751A (zh) | 重組Ｆｃ域—ＩＬ２變異體多肽及與膜錨定抗原結合多肽的組合療法 | |
| CN118562015B (zh) | 一种针对cd20/cd3的双特异性抗体及其制备方法和应用 | |
| US20260028412A1 (en) | Antibodies and fragments specific for b-cell maturation antigen and uses thereof | |
| WO2026021525A1 (en) | Gprc5d binding moieties and uses thereof | |
| WO2025233304A1 (en) | Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides | |
| TW202608912A (zh) | 重組Ｆｃ域－ＩＬ７變異體多肽及與膜錨定抗原結合多肽的組合療法 | |
| WO2024165049A1 (zh) | 抗cdh6的抗体及其用途 | |
| CA3204050A1 (en) | Anti-cd72 nanobodies for immunotherapy |